首页 > 最新文献

Health Policy and Technology最新文献

英文 中文
Innovative approaches to strengthening health systems in LMIC's 加强低收入和中等收入国家卫生系统的创新方法
IF 3.7 3区 医学 Q1 HEALTH POLICY & SERVICES Pub Date : 2025-08-01 DOI: 10.1016/j.hlpt.2024.100970
Diana Frost , Mufti Mahmud , M.Shamim Kaiser , David Musoke , Paulette Henry , Shariful Islam
None.
没有。
{"title":"Innovative approaches to strengthening health systems in LMIC's","authors":"Diana Frost ,&nbsp;Mufti Mahmud ,&nbsp;M.Shamim Kaiser ,&nbsp;David Musoke ,&nbsp;Paulette Henry ,&nbsp;Shariful Islam","doi":"10.1016/j.hlpt.2024.100970","DOIUrl":"10.1016/j.hlpt.2024.100970","url":null,"abstract":"<div><div>None.</div></div>","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"14 4","pages":"Article 100970"},"PeriodicalIF":3.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144827290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Digital health inclusion towards achieving universal health coverage for Bangladesh utilizing general practitioner model 利用全科医生模式实现孟加拉国全民健康覆盖的数字健康包容
IF 3.7 3区 医学 Q1 HEALTH POLICY & SERVICES Pub Date : 2025-08-01 DOI: 10.1016/j.hlpt.2023.100731
Moinul H. Chowdhury , Rony Chowdhury Ripan , A.K.M. Nazmul Islam , Rubaiyat Alim Hridhee , Farhana Sarker , Sheikh Mohammed Shariful Islam , Khondaker A. Mamun

Objective

Bangladesh's health care system, particularly in rural areas, experiences enormous obstacles in providing complete preventive and primary healthcare services due to the lack of adequate healthcare facilities, resource constraints, and a non-functional referral system. To alleviate these problems, in this study, we introduce the digital general practitioner (GP) model for rural Bangladesh, digital platforms and present a statistical analysis of the data that was gathered from the pilot project.

Methods

A total of 12,746 people were provided regular health services during the pilot project, from all genders and age groups, and provided their socio-demographic and healthcare-related data. We analyzed healthcare-related data by carrying out both descriptive and inferential statistics.

Results

By utilizing this digital GP model, rural residents can receive routine health screenings at their homes, identify health risks early, receive consultation and health education, and be referred to GP and upper-level health facilities as needed. We found that hypertension was more prevalent (4.84% of the served population), and cancer was the least prevalent of all the NCDs in the studied population (0.05% of the served population). The population for stroke, hypertension, diabetes increased until the 50–59 age range as age increased, following which the population proportion declined as age increased. Additionally, 3.96% of young females were severely malnourished, comparably higher proportion than young males (2.34%).

Conclusion

NCDs such as hypertension, diabetes was prevalent among rural people. Necessary steps should be taken to raise preventive and primary healthcare awareness among rural people.

Public interest summary

The absence of proper healthcare facilities, resource constraints, and a non-functional referral system hamper Bangladesh's health care system's ability to provide comprehensive preventive and primary healthcare services in rural area. As a result, patients develop advanced ailments, including non-communicable diseases (NCDs), and must seek treatment at an expensive specialty hospital. To resolve this issue, we introduce a digital GP model for rural Bangladesh, then show digital platforms that use the concept, and lastly summarize significant findings from the piloted digital GP model. By utilizing this digital GP model, rural residents can receive routine health screenings at their homes, identify health risks early, receive consultation and health education, and be referred to GP and upper-level health facilities as need. From our data analysis, we discovered high burden of NCDs such as hypertension and diabetes in the piloted area. Necessary steps should be taken to raise preventive and primary healthcare awareness among rural people.
孟加拉国的卫生保健系统,特别是在农村地区,在提供完整的预防和初级卫生保健服务方面遇到了巨大的障碍,原因是缺乏足够的卫生保健设施,资源限制,以及功能不健全的转诊系统。为了缓解这些问题,在本研究中,我们为孟加拉国农村引入了数字全科医生(GP)模型、数字平台,并对从试点项目中收集的数据进行了统计分析。方法在试点项目期间,共有来自所有性别和年龄组的12,746人获得了定期保健服务,并提供了他们的社会人口和保健相关数据。我们通过描述性和推断性统计来分析医疗保健相关数据。结果利用数字全科医生模式,农村居民可以在家中进行常规健康筛查,及早发现健康风险,接受咨询和健康教育,并根据需要转诊到全科医生和上级卫生机构。我们发现高血压更为普遍(占服务人群的4.84%),而癌症是所有非传染性疾病中发病率最低的(占服务人群的0.05%)。在50-59岁年龄段,中风、高血压、糖尿病患者的比例随着年龄的增长而增加,随后随着年龄的增长而下降。女性严重营养不良的比例为3.96%,高于男性(2.34%)。结论农村人群中高血压、糖尿病等非传染性疾病较为普遍。应采取必要步骤,提高农村人口对预防和初级保健的认识。由于缺乏适当的卫生保健设施,资源有限,转诊系统功能不全,孟加拉国卫生保健系统无法在农村地区提供全面的预防和初级卫生保健服务。结果,患者患上了晚期疾病,包括非传染性疾病(NCDs),必须在昂贵的专科医院寻求治疗。为了解决这一问题,我们为孟加拉国农村引入了数字全科医生模型,然后展示了使用该概念的数字平台,最后总结了试点数字全科医生模型的重要发现。利用这种数字全科医生模式,农村居民可以在家中接受常规健康检查,及早发现健康风险,接受咨询和健康教育,并根据需要转诊到全科医生和上级卫生机构。通过数据分析,我们发现试点地区高血压、糖尿病等非传染性疾病负担较高。应采取必要步骤,提高农村人口对预防和初级保健的认识。
{"title":"Digital health inclusion towards achieving universal health coverage for Bangladesh utilizing general practitioner model","authors":"Moinul H. Chowdhury ,&nbsp;Rony Chowdhury Ripan ,&nbsp;A.K.M. Nazmul Islam ,&nbsp;Rubaiyat Alim Hridhee ,&nbsp;Farhana Sarker ,&nbsp;Sheikh Mohammed Shariful Islam ,&nbsp;Khondaker A. Mamun","doi":"10.1016/j.hlpt.2023.100731","DOIUrl":"10.1016/j.hlpt.2023.100731","url":null,"abstract":"<div><h3>Objective</h3><div>Bangladesh's health care system, particularly in rural areas, experiences enormous obstacles in providing complete preventive and primary healthcare services due to the lack of adequate healthcare facilities, resource constraints, and a non-functional referral system. To alleviate these problems, in this study, we introduce the digital general practitioner (GP) model for rural Bangladesh, digital platforms and present a statistical analysis of the data that was gathered from the pilot project.</div></div><div><h3>Methods</h3><div>A total of 12,746 people were provided regular health services during the pilot project, from all genders and age groups, and provided their socio-demographic and healthcare-related data. We analyzed healthcare-related data by carrying out both descriptive and inferential statistics.</div></div><div><h3>Results</h3><div>By utilizing this digital GP model, rural residents can receive routine health screenings at their homes, identify health risks early, receive consultation and health education, and be referred to GP and upper-level health facilities as needed. We found that hypertension was more prevalent (4.84% of the served population), and cancer was the least prevalent of all the NCDs in the studied population (0.05% of the served population). The population for stroke, hypertension, diabetes increased until the 50–59 age range as age increased, following which the population proportion declined as age increased. Additionally, 3.96% of young females were severely malnourished, comparably higher proportion than young males (2.34%).</div></div><div><h3>Conclusion</h3><div>NCDs such as hypertension, diabetes was prevalent among rural people. Necessary steps should be taken to raise preventive and primary healthcare awareness among rural people.</div></div><div><h3>Public interest summary</h3><div>The absence of proper healthcare facilities, resource constraints, and a non-functional referral system hamper Bangladesh's health care system's ability to provide comprehensive preventive and primary healthcare services in rural area. As a result, patients develop advanced ailments, including non-communicable diseases (NCDs), and must seek treatment at an expensive specialty hospital. To resolve this issue, we introduce a digital GP model for rural Bangladesh, then show digital platforms that use the concept, and lastly summarize significant findings from the piloted digital GP model. By utilizing this digital GP model, rural residents can receive routine health screenings at their homes, identify health risks early, receive consultation and health education, and be referred to GP and upper-level health facilities as need. From our data analysis, we discovered high burden of NCDs such as hypertension and diabetes in the piloted area. Necessary steps should be taken to raise preventive and primary healthcare awareness among rural people.</div></div>","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"14 4","pages":"Article 100731"},"PeriodicalIF":3.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48926968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating the moderating effect of COVID-19 on Pakistan's healthcare sector 调查2019冠状病毒病对巴基斯坦医疗保健部门的缓和作用
IF 3.7 3区 医学 Q1 HEALTH POLICY & SERVICES Pub Date : 2025-08-01 DOI: 10.1016/j.hlpt.2025.101040
Saqib Mehmood , Samera Nazir , Jianqiang Fan (Vice Dean) , Zarish Nazir (MS Scholar) , Sana Nazir (MSs Scholar)

Background

The COVID-19 pandemic has drastically disrupted health service delivery, particularly in resource-limited countries such as Pakistan. This study aims to assess how Pakistan's healthcare infrastructure has adapted in response to the pandemic, focusing on governmental strategies, technology integration, and socioeconomic factors influencing public health outcomes.

Materials and Methods

A stratified random sampling approach was employed, distributing 300 questionnaires to management and staff across hospitals in Punjab. The data collected were analyzed using PLS-SEM4 software to uncover the relationships among the variables of interest.

Results

The findings reveal the complex impacts of the pandemic on healthcare delivery. Effective government regulations were identified as crucial in managing the crisis, while technology integration emerged as a key factor in enhancing healthcare services. Socioeconomic conditions were found to significantly affect public health outcomes, underscoring the interconnection of these components.

Conclusion

This study provides valuable insights for policymakers, healthcare professionals, and researchers aiming to strengthen the resilience of Pakistan's healthcare system. By applying resilience theory, public health policy theory, and complex adaptive systems theory, the research emphasizes the need for adaptability, effective governance, and systemic interconnection in addressing public health challenges. The implications extend globally, offering strategies to improve healthcare infrastructure during crises.
COVID-19大流行严重扰乱了卫生服务的提供,特别是在巴基斯坦等资源有限的国家。本研究旨在评估巴基斯坦的医疗基础设施如何适应疫情,重点关注政府战略、技术整合和影响公共卫生结果的社会经济因素。材料与方法采用分层随机抽样的方法,向旁遮普省各医院的管理人员和工作人员发放了300份问卷。收集的数据使用PLS-SEM4软件进行分析,以揭示感兴趣的变量之间的关系。结果研究结果揭示了疫情对医疗服务的复杂影响。有效的政府法规被认为是管理危机的关键,而技术整合则成为加强医疗保健服务的关键因素。研究发现,社会经济条件显著影响公共卫生结果,强调了这些组成部分的相互联系。本研究为决策者、医疗保健专业人员和旨在加强巴基斯坦医疗保健系统弹性的研究人员提供了有价值的见解。通过运用弹性理论、公共卫生政策理论和复杂适应系统理论,强调应对公共卫生挑战需要适应性、有效治理和系统互联。其影响延伸至全球,提供了在危机期间改善医疗基础设施的战略。
{"title":"Investigating the moderating effect of COVID-19 on Pakistan's healthcare sector","authors":"Saqib Mehmood ,&nbsp;Samera Nazir ,&nbsp;Jianqiang Fan (Vice Dean) ,&nbsp;Zarish Nazir (MS Scholar) ,&nbsp;Sana Nazir (MSs Scholar)","doi":"10.1016/j.hlpt.2025.101040","DOIUrl":"10.1016/j.hlpt.2025.101040","url":null,"abstract":"<div><h3>Background</h3><div>The COVID-19 pandemic has drastically disrupted health service delivery, particularly in resource-limited countries such as Pakistan. This study aims to assess how Pakistan's healthcare infrastructure has adapted in response to the pandemic, focusing on governmental strategies, technology integration, and socioeconomic factors influencing public health outcomes.</div></div><div><h3>Materials and Methods</h3><div>A stratified random sampling approach was employed, distributing 300 questionnaires to management and staff across hospitals in Punjab. The data collected were analyzed using PLS-SEM4 software to uncover the relationships among the variables of interest.</div></div><div><h3>Results</h3><div>The findings reveal the complex impacts of the pandemic on healthcare delivery. Effective government regulations were identified as crucial in managing the crisis, while technology integration emerged as a key factor in enhancing healthcare services. Socioeconomic conditions were found to significantly affect public health outcomes, underscoring the interconnection of these components.</div></div><div><h3>Conclusion</h3><div>This study provides valuable insights for policymakers, healthcare professionals, and researchers aiming to strengthen the resilience of Pakistan's healthcare system. By applying resilience theory, public health policy theory, and complex adaptive systems theory, the research emphasizes the need for adaptability, effective governance, and systemic interconnection in addressing public health challenges. The implications extend globally, offering strategies to improve healthcare infrastructure during crises.</div></div>","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"14 4","pages":"Article 101040"},"PeriodicalIF":3.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144827286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
E-Prescription: A practical application of information and communications technology in perspective of Bangladesh 电子处方:从孟加拉国的角度看信息和通信技术的实际应用
IF 3.7 3区 医学 Q1 HEALTH POLICY & SERVICES Pub Date : 2025-08-01 DOI: 10.1016/j.hlpt.2023.100810
M. A. Khan, Md. Rabiul Islam, Asif Rahman, Afsana Mim, Rasel Ahmmed

Objectives

The healthcare management authorities are responsible for delivering convenient services to the patients. The traditional healthcare management system is quite old and impractical in many cases, including a physical visit. Additionally, the COVID-19 epidemic makes the existing system unattainable, which creates an uncomfortable situation for visiting doctor's chambers that is risky both for doctors and patients. An electronic-prescription (e-prescription) management system can switch the existing one to the online appointment and doctor consulting system. Many developed countries have already adopted such e-prescription management systems, although low-and-middle-income countries (LMICs) like Bangladesh are apathetic. So implementing e-prescription management systems in all countries, including Bangladesh, is the demand of time, especially when information and communication technologies (ICT) are at hand.

Method

We design, develop and test an ICT-based online doctor and patient management system utilizing the latest software and web development tools.

Results

In the developed e-prescription management system, the patient can visit their profile to make an appointment according to their need and doctor's availability. After that, the patient consults with the doctor based on the appointment's approval by the admin panel. Finally, the patient receives an online e-prescription and collects the medicine from a registered pharmacy with access to the online e-prescription. The e-prescription management system records patient history, including e-prescription, making handling patients easy.

Conclusion

The proper use of the developed e-prescription management system will solve many existing problems of the existing healthcare management system, including many concerns that arise due to the advent of COVID-19.
目的医疗管理机构有责任为患者提供便捷的服务。传统的医疗保健管理系统在很多情况下都是相当陈旧和不切实际的,包括身体检查。再加上新型冠状病毒感染症(COVID-19)的扩散,使现有的制度变得难以实现,这给医生和患者带来了很大的风险。电子处方管理系统可以将现有的电子处方管理系统转换为网上预约和医生咨询系统。许多发达国家已经采用了这种电子处方管理系统,尽管孟加拉国等低收入和中等收入国家对此漠不关心。因此,在包括孟加拉国在内的所有国家实施电子处方管理系统是时间的要求,特别是在掌握信息和通信技术(ICT)的情况下。方法利用最新的软件和web开发工具,设计、开发和测试基于信息通信技术的在线医患管理系统。结果在开发的电子处方管理系统中,患者可以根据自己的需要和医生的空闲时间访问个人档案进行预约。之后,患者根据管理小组批准的预约向医生咨询。最后,患者收到在线电子处方,并从可访问在线电子处方的注册药房取药。电子处方管理系统记录了患者的历史,包括电子处方,使处理患者变得容易。结论开发的电子处方管理系统的正确使用,将解决现有医疗管理系统存在的诸多问题,包括新冠肺炎疫情带来的诸多担忧。
{"title":"E-Prescription: A practical application of information and communications technology in perspective of Bangladesh","authors":"M. A. Khan,&nbsp;Md. Rabiul Islam,&nbsp;Asif Rahman,&nbsp;Afsana Mim,&nbsp;Rasel Ahmmed","doi":"10.1016/j.hlpt.2023.100810","DOIUrl":"10.1016/j.hlpt.2023.100810","url":null,"abstract":"<div><h3>Objectives</h3><div>The healthcare management authorities are responsible for delivering convenient services to the patients. The traditional healthcare management system is quite old and impractical in many cases, including a physical visit. Additionally, the COVID-19 epidemic makes the existing system unattainable, which creates an uncomfortable situation for visiting doctor's chambers that is risky both for doctors and patients. An electronic-prescription (e-prescription) management system can switch the existing one to the online appointment and doctor consulting system. Many developed countries have already adopted such e-prescription management systems, although low-and-middle-income countries (LMICs) like Bangladesh are apathetic. So implementing e-prescription management systems in all countries, including Bangladesh, is the demand of time, especially when information and communication technologies (ICT) are at hand.</div></div><div><h3>Method</h3><div>We design, develop and test an ICT-based online doctor and patient management system utilizing the latest software and web development tools.</div></div><div><h3>Results</h3><div>In the developed e-prescription management system, the patient can visit their profile to make an appointment according to their need and doctor's availability. After that, the patient consults with the doctor based on the appointment's approval by the admin panel. Finally, the patient receives an online e-prescription and collects the medicine from a registered pharmacy with access to the online e-prescription. The e-prescription management system records patient history, including e-prescription, making handling patients easy.</div></div><div><h3>Conclusion</h3><div>The proper use of the developed e-prescription management system will solve many existing problems of the existing healthcare management system, including many concerns that arise due to the advent of COVID-19.</div></div>","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"14 4","pages":"Article 100810"},"PeriodicalIF":3.7,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134934267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quantifying pharmaceutical and medical device industry-physician financial ties: An analysis of honorarium payments to Japanese medical association leadership between 2019 and 2021 量化制药和医疗器械行业-医生的财务关系:2019年至2021年日本医学协会领导层的酬金支付分析
IF 3.7 3区 医学 Q1 HEALTH POLICY & SERVICES Pub Date : 2025-07-28 DOI: 10.1016/j.hlpt.2025.101081
Akemi Hara , Tetsuya Tanimoto , Piotr Ozieranski , James Larkin , Michioki Endo , Hiroaki Saito , Akihiko Ozaki

Objective

To assess the extent and distribution of pharmaceutical and medical device industry honorarium payments to medical association leadership, enhancing our understanding of industry-physician financial ties in Japan.

Methods

We conducted a retrospective analysis of publicly disclosed payment data from pharmaceutical companies affiliated with the Japan Pharmaceutical Manufacturers Association and medical device companies affiliated with the Medical Devices Network. Data covered honorarium payments for speaking, writing, and consulting to board members of 18 major professional medical associations from 2019 to 2021.

Results

Of the 399 executive board members, 373 (93.5 %) received payments totaling $15.99 million. The median payment per member over the three years was $22,529, (interquartile range [IQR], $7230.8–$57,223.9). Payments were concentrated, with four professional medical associations—representing Internal Medicine ($2.97 million), Ophthalmology ($1.78 million), Dermatology ($1.78 million), and Urology ($1.87 million)—accounting for 52.5 % of the total. Surgical specialties received a higher proportion of payments from medical device companies, while non-surgical specialties – pharmaceutical companies. Payments declined in 2020, coinciding with the COVID-19 pandemic, recovering by 2021. None of the 18 associations' leadership publicly disclosed their board members' financial ties.

Conclusions

We found extensive and concentrated ties between industry and medical association leadership in Japan, with the pharmaceutical and medical device sectors each displaying distinctive payment patterns. The substantial scale of payments and limited transparency displayed by the association highlight the urgent need for legally mandated disclosure, including specialty-specific solutions.
目的评估制药和医疗器械行业向医疗协会领导支付酬金的程度和分布,增强我们对日本行业-医生财务关系的了解。方法回顾性分析日本医药工业协会所属制药公司和医疗器械网络所属医疗器械公司公开披露的支付数据。数据涵盖了2019年至2021年期间向18个主要专业医学协会董事会成员支付的演讲、写作和咨询酬金。结果在399名执行董事会成员中,373名(93.5%)获得了总计1599万美元的薪酬。每位会员在三年内支付的中位数为22,529美元(四分位数区间[IQR]为7230.8美元至57,223.9美元)。付款集中在四个专业医学协会,分别代表内科(297万美元)、眼科(178万美元)、皮肤科(178万美元)和泌尿科(187万美元),占总数的52.5%。外科专业从医疗器械公司获得的付款比例较高,而非外科专业-制药公司。在2019冠状病毒病大流行期间,支付额在2020年下降,到2021年恢复。18家协会的领导层都没有公开披露其董事会成员的财务关系。我们发现日本的行业和医疗协会领导层之间存在广泛而集中的联系,制药和医疗器械行业各自表现出独特的支付模式。该协会所显示的巨额支付和有限的透明度凸显了法律强制披露的迫切需要,包括专门的解决方案。
{"title":"Quantifying pharmaceutical and medical device industry-physician financial ties: An analysis of honorarium payments to Japanese medical association leadership between 2019 and 2021","authors":"Akemi Hara ,&nbsp;Tetsuya Tanimoto ,&nbsp;Piotr Ozieranski ,&nbsp;James Larkin ,&nbsp;Michioki Endo ,&nbsp;Hiroaki Saito ,&nbsp;Akihiko Ozaki","doi":"10.1016/j.hlpt.2025.101081","DOIUrl":"10.1016/j.hlpt.2025.101081","url":null,"abstract":"<div><h3>Objective</h3><div>To assess the extent and distribution of pharmaceutical and medical device industry honorarium payments to medical association leadership, enhancing our understanding of industry-physician financial ties in Japan.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of publicly disclosed payment data from pharmaceutical companies affiliated with the Japan Pharmaceutical Manufacturers Association and medical device companies affiliated with the Medical Devices Network. Data covered honorarium payments for speaking, writing, and consulting to board members of 18 major professional medical associations from 2019 to 2021.</div></div><div><h3>Results</h3><div>Of the 399 executive board members, 373 (93.5 %) received payments totaling $15.99 million. The median payment per member over the three years was $22,529, (interquartile range [IQR], $7230.8–$57,223.9). Payments were concentrated, with four professional medical associations—representing Internal Medicine ($2.97 million), Ophthalmology ($1.78 million), Dermatology ($1.78 million), and Urology ($1.87 million)—accounting for 52.5 % of the total. Surgical specialties received a higher proportion of payments from medical device companies, while non-surgical specialties – pharmaceutical companies. Payments declined in 2020, coinciding with the COVID-19 pandemic, recovering by 2021. None of the 18 associations' leadership publicly disclosed their board members' financial ties.</div></div><div><h3>Conclusions</h3><div>We found extensive and concentrated ties between industry and medical association leadership in Japan, with the pharmaceutical and medical device sectors each displaying distinctive payment patterns. The substantial scale of payments and limited transparency displayed by the association highlight the urgent need for legally mandated disclosure, including specialty-specific solutions.</div></div>","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"14 6","pages":"Article 101081"},"PeriodicalIF":3.7,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144830493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The digital equity paradox: When good intentions pave the road to technological stratification 数字公平悖论:当善意为技术分层铺平道路时
IF 3.7 3区 医学 Q1 HEALTH POLICY & SERVICES Pub Date : 2025-07-28 DOI: 10.1016/j.hlpt.2025.101079
Y. Tony Yang
{"title":"The digital equity paradox: When good intentions pave the road to technological stratification","authors":"Y. Tony Yang","doi":"10.1016/j.hlpt.2025.101079","DOIUrl":"10.1016/j.hlpt.2025.101079","url":null,"abstract":"","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"14 5","pages":"Article 101079"},"PeriodicalIF":3.7,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144770677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-utility analysis of add-on SGLT2 inhibitors for heart failure with reduced ejection fraction in India 印度附加SGLT2抑制剂治疗心力衰竭伴射血分数降低的成本-效用分析
IF 3.7 3区 医学 Q1 HEALTH POLICY & SERVICES Pub Date : 2025-07-26 DOI: 10.1016/j.hlpt.2025.101077
Akhil Sasidharan , Sajith Kumar S , Suchitralakshmi G , Kavitha Rajsekar , Bhavani Shankara Bagepally

Background

Heart failure with reduced ejection fraction (HFrEF) imposes significant clinical burden and costs in India. While sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated clinical benefits, their cost-effectiveness within the Indian healthcare perspective remains unassessed.

Methods

A Markov model with a lifetime horizon and one-year cycles was developed to evaluate the cost-effectiveness of SGLT2i as an add-on therapy to standard of care (SoC) compared to SoC alone in patients with HFrEF in India. The analysis adopted an abridged societal perspective, incorporating direct medical and non-medical costs, as well as out-of-pocket expenditures. Clinical efficacy data were obtained from meta-analyses while cost data were sourced from published Indian studies and databases. Costs (2024) and Quality-Adjusted Life Years (QALYs) were used to determine the incremental cost-utility ratio (ICURs). A willingness-to-pay (WTP) threshold of one time India’s GDP per capita [₹2,26,765 (US$2,710)] per QALY was used. Uncertainty was assessed through one-way sensitivity analysis (OWSA) and probabilistic sensitivity analysis (PSA). Scenario analyses were conducted to test structural assumptions, and a price threshold analysis was performed to estimate the price at which SGLT2i would become cost-effective.

Results

Despite additional gains in QALYs, add-on SGLT2i were not cost-effective at their current market prices, with an ICUR of ₹6,12,406 (US$7,318) per QALY. Cost-effectiveness estimates were sensitive to variations in drug pricing. PSA confirmed the robustness of these findings. Price threshold analysis indicated that a 71 % reduction in the average market prices for SGLT2i would be required for cost-effectiveness.

Conclusions

While SGLT2i improve clinical outcomes in HFrEF, their current cost renders them not cost-effective in the Indian healthcare setting. Substantial price reductions, potentially through price negotiations with manufacturers, are necessary to enhance their affordability and optimize resource allocation for Heart failure management in India.
背景:心力衰竭伴射血分数降低(HFrEF)在印度造成了巨大的临床负担和费用。虽然钠-葡萄糖共转运蛋白-2抑制剂(SGLT2i)已显示出临床益处,但其在印度医疗保健方面的成本效益仍未得到评估。方法建立了一个具有生命周期和一年周期的马尔可夫模型,以评估SGLT2i作为标准治疗(SoC)的附加治疗与单独使用SoC在印度HFrEF患者中的成本效益。该分析采用了简略的社会观点,纳入了直接医疗和非医疗费用以及自付费用。临床疗效数据来自荟萃分析,而成本数据来自已发表的印度研究和数据库。使用成本(2024年)和质量调整寿命年(QALYs)来确定增量成本效用比(ICURs)。每个QALY的支付意愿(WTP)阈值为印度人均GDP的一倍[2,26,765卢比(2,710美元)]。通过单向敏感性分析(OWSA)和概率敏感性分析(PSA)评估不确定性。进行情景分析以检验结构假设,并进行价格阈值分析以估计sgltti具有成本效益的价格。结果尽管QALY有额外的收益,但附加的SGLT2i在目前的市场价格上并不具有成本效益,每个QALY的ICUR为6,12,406卢比(7,318美元)。成本效益估计对药品定价的变化很敏感。PSA证实了这些发现的稳健性。价格阈值分析表明,SGLT2i的平均市场价格需要降低71%才能达到成本效益。结论:虽然SGLT2i改善了HFrEF的临床结果,但其目前的成本使其在印度医疗保健环境中不具有成本效益。在印度,有必要通过与制造商进行价格谈判来大幅降低价格,以提高他们的负担能力,并优化心力衰竭管理的资源配置。
{"title":"Cost-utility analysis of add-on SGLT2 inhibitors for heart failure with reduced ejection fraction in India","authors":"Akhil Sasidharan ,&nbsp;Sajith Kumar S ,&nbsp;Suchitralakshmi G ,&nbsp;Kavitha Rajsekar ,&nbsp;Bhavani Shankara Bagepally","doi":"10.1016/j.hlpt.2025.101077","DOIUrl":"10.1016/j.hlpt.2025.101077","url":null,"abstract":"<div><h3>Background</h3><div>Heart failure with reduced ejection fraction (HFrEF) imposes significant clinical burden and costs in India. While sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated clinical benefits, their cost-effectiveness within the Indian healthcare perspective remains unassessed.</div></div><div><h3>Methods</h3><div>A Markov model with a lifetime horizon and one-year cycles was developed to evaluate the cost-effectiveness of SGLT2i as an add-on therapy to standard of care (SoC) compared to SoC alone in patients with HFrEF in India. The analysis adopted an abridged societal perspective, incorporating direct medical and non-medical costs, as well as out-of-pocket expenditures. Clinical efficacy data were obtained from meta-analyses while cost data were sourced from published Indian studies and databases. Costs (2024) and Quality-Adjusted Life Years (QALYs) were used to determine the incremental cost-utility ratio (ICURs). A willingness-to-pay (WTP) threshold of one time India’s GDP per capita [₹2,26,765 (US$2,710)] per QALY was used. Uncertainty was assessed through one-way sensitivity analysis (OWSA) and probabilistic sensitivity analysis (PSA). Scenario analyses were conducted to test structural assumptions, and a price threshold analysis was performed to estimate the price at which SGLT2i would become cost-effective.</div></div><div><h3>Results</h3><div>Despite additional gains in QALYs, add-on SGLT2i were not cost-effective at their current market prices, with an ICUR of ₹6,12,406 (US$7,318) per QALY. Cost-effectiveness estimates were sensitive to variations in drug pricing. PSA confirmed the robustness of these findings. Price threshold analysis indicated that a 71 % reduction in the average market prices for SGLT2i would be required for cost-effectiveness.</div></div><div><h3>Conclusions</h3><div>While SGLT2i improve clinical outcomes in HFrEF, their current cost renders them not cost-effective in the Indian healthcare setting. Substantial price reductions, potentially through price negotiations with manufacturers, are necessary to enhance their affordability and optimize resource allocation for Heart failure management in India.</div></div>","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"14 6","pages":"Article 101077"},"PeriodicalIF":3.7,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144772788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence in healthcare: Tailoring education to meet EU AI-Act standards 医疗保健中的人工智能:定制教育以满足欧盟人工智能法案标准
IF 3.7 3区 医学 Q1 HEALTH POLICY & SERVICES Pub Date : 2025-07-25 DOI: 10.1016/j.hlpt.2025.101078
Elena Bignami , Luigino Jalale Darhour , Wolfgang Buhre , Maurizio Cecconi , Valentina Bellini
The integration of Artificial Intelligence (AI) in Intensive Care Units (ICUs) has the potential to transform critical care by enhancing diagnosis, management, and clinical decision-making. Generative and Predictive AI technologies offer new opportunities for personalized care and risk stratification, but their implementation must prioritize ethical standards, patient safety, and the sustainability of care delivery. With the EU AI-Act entering into force in February 2025, a structured and responsible adoption of AI is now imperative. This article outlines a strategic framework for ICU AI integration, emphasizing the importance of a formal declaration of intent by each unit, detailing current AI-use, implementation plans, and governance strategies. Central to this approach is the development of tailored AI education programs adapted to four distinct professional profiles, ranging from experienced clinicians with limited AI knowledge to new intensivists with strong AI backgrounds but limited clinical experience. Training must foster critical thinking, contextual interpretation, and a balanced relationship between AI tools and human judgment. A multidisciplinary support team should oversee ethical AI-use and continuous performance monitoring. Ultimately, aligning regulatory compliance with targeted education and practical implementation could enable a safe, effective, and ethically grounded use of AI in intensive care. This balanced approach would support a culture of transparency and accountability, while preserving the central role of human clinical reasoning and improving the overall quality of ICU care.
人工智能(AI)在重症监护病房(icu)的整合有可能通过加强诊断、管理和临床决策来改变重症监护。生成式和预测性人工智能技术为个性化护理和风险分层提供了新的机会,但它们的实施必须优先考虑道德标准、患者安全和护理服务的可持续性。随着《欧盟人工智能法案》于2025年2月生效,人工智能的结构化和负责任采用现在势在必行。本文概述了ICU人工智能集成的战略框架,强调了每个单元正式声明意图的重要性,详细说明了当前人工智能的使用、实施计划和治理策略。这种方法的核心是开发量身定制的人工智能教育计划,以适应四种不同的专业概况,从经验丰富的临床医生,有限的人工智能知识,到具有强大的人工智能背景,但临床经验有限的新重症医师。培训必须培养批判性思维、上下文解释以及人工智能工具和人类判断之间的平衡关系。一个多学科支持团队应该监督合乎道德的人工智能使用和持续的绩效监测。最终,将监管合规与有针对性的教育和实际实施相结合,可以使人工智能在重症监护中得到安全、有效和合乎道德的使用。这种平衡的方法将支持透明和问责的文化,同时保留人类临床推理的核心作用,并提高ICU护理的整体质量。
{"title":"Artificial intelligence in healthcare: Tailoring education to meet EU AI-Act standards","authors":"Elena Bignami ,&nbsp;Luigino Jalale Darhour ,&nbsp;Wolfgang Buhre ,&nbsp;Maurizio Cecconi ,&nbsp;Valentina Bellini","doi":"10.1016/j.hlpt.2025.101078","DOIUrl":"10.1016/j.hlpt.2025.101078","url":null,"abstract":"<div><div>The integration of Artificial Intelligence (AI) in Intensive Care Units (ICUs) has the potential to transform critical care by enhancing diagnosis, management, and clinical decision-making. Generative and Predictive AI technologies offer new opportunities for personalized care and risk stratification, but their implementation must prioritize ethical standards, patient safety, and the sustainability of care delivery. With the EU AI-Act entering into force in February 2025, a structured and responsible adoption of AI is now imperative. This article outlines a strategic framework for ICU AI integration, emphasizing the importance of a formal declaration of intent by each unit, detailing current AI-use, implementation plans, and governance strategies. Central to this approach is the development of tailored AI education programs adapted to four distinct professional profiles, ranging from experienced clinicians with limited AI knowledge to new intensivists with strong AI backgrounds but limited clinical experience. Training must foster critical thinking, contextual interpretation, and a balanced relationship between AI tools and human judgment. A multidisciplinary support team should oversee ethical AI-use and continuous performance monitoring. Ultimately, aligning regulatory compliance with targeted education and practical implementation could enable a safe, effective, and ethically grounded use of AI in intensive care. This balanced approach would support a culture of transparency and accountability, while preserving the central role of human clinical reasoning and improving the overall quality of ICU care.</div></div>","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"14 6","pages":"Article 101078"},"PeriodicalIF":3.7,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144721584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Guiding stakeholder involvement in health technology assessment for medical devices: A novel approach for clarifying stakeholders’ roles and contributions 指导利益相关者参与医疗器械卫生技术评估:澄清利益相关者角色和贡献的新方法
IF 3.7 3区 医学 Q1 HEALTH POLICY & SERVICES Pub Date : 2025-07-23 DOI: 10.1016/j.hlpt.2025.101075
Liliana Freitas , Mónica D. Oliveira , Ana C.L. Vieira

Objectives

Stakeholder involvement is recognized as essential in Health Technology Assessment (HTA), yet engagement remains insufficient, particularly in medical device (MD) evaluations. Literature on how to systematically identify and integrate stakeholders remains scarce. This study proposes a reflective framework to support HTA practitioners think about stakeholder inclusion and applies it to explore perspectives within the medical device context in Portugal.

Methods

We adapted Ulrich’s Critical Systems Heuristics (CSH) as a conceptual lens to structure reflection on stakeholder roles and contributions in MD HTA. The framework is organized around four sources of influence (motivation, control, knowledge, and legitimacy) and was operationalized through 26 semi-structured interviews with experts from Portugal’s HTA agency, hospitals, patient associations, and industry. Interview data were analysed using directed content analysis and the Framework Method, allowing to contrast current ('is') and ideal ('ought') views within each source of influence. The common themes were then used to construct interpretative narratives that captured rationales for stakeholder inclusion.

Results

The application of the framework revealed context-specific insights into stakeholder engagement in MD evaluation. Findings show stakeholder roles in MD evaluations extend beyond traditional classifications. For each CSH source of influence, rationales and conditions for stakeholder engagement were identified. Under motivation, stakeholders identified diverse purposes and measures of success, ranging from improved patient access to innovation to system-wide resource optimization. Under control, providers, purchasers, and payers were seen as central decision-makers, yet ideal processes included multidisciplinary governance and clearer procedural support. Under knowledge, multiple actors (including patients) were valued as contributors of contextual expertise, but gaps were highlighted in methodological tools. Under legitimacy, patients and the public were underrepresented and called for stronger mechanisms for direct involvement and broader societal alignment. Across all sources of influence, significant gaps were found between current practices and stakeholder expectations to highlight areas for development.

Conclusions

Rather than prescribing fixed engagement procedures, the proposed reflective framework offers a structured lens to support HTA practitioners in reasoning through stakeholder roles, values, and contributions in MD evaluations. The framework is transferable to other decision-making contexts and fosters more transparent and inclusive deliberation.
利益相关者的参与在卫生技术评估(HTA)中被认为是必不可少的,但参与仍然不足,特别是在医疗器械(MD)评估中。关于如何系统地识别和整合利益相关者的文献仍然很少。本研究提出了一个反思性框架,以支持HTA从业者思考利益相关者的包容,并将其应用于探索葡萄牙医疗器械背景下的观点。方法我们采用了Ulrich的关键系统启发式(CSH)作为概念透镜来构建对MD HTA中利益相关者角色和贡献的反思。该框架围绕四个影响来源(动机、控制、知识和合法性)进行组织,并通过对来自葡萄牙HTA机构、医院、患者协会和行业的专家进行26次半结构化访谈来实施。使用定向内容分析和框架方法分析访谈数据,允许在每个影响来源内对比当前(“是”)和理想(“应该”)观点。然后使用共同主题来构建解释性叙述,以捕获利益相关者包容的基本原理。结果该框架的应用揭示了在MD评估中利益相关者参与的具体情况。研究结果表明,利益相关者在MD评估中的作用超出了传统的分类。对于每一个CSH的影响来源,确定了利益相关者参与的理由和条件。在激励下,利益相关者确定了不同的目标和成功措施,从改善患者获得创新的机会到全系统资源优化。在控制下,提供者、购买者和支付者被视为中心决策者,然而理想的过程包括多学科治理和更清晰的程序支持。在知识方面,多个行为者(包括患者)被视为情境专业知识的贡献者,但方法工具方面的差距突出。在合法性下,患者和公众的代表不足,并呼吁建立更强有力的直接参与机制和更广泛的社会协调。在所有影响来源中,发现当前做法与利益攸关方强调发展领域的期望之间存在重大差距。建议的反思框架没有规定固定的参与程序,而是提供了一个结构化的视角,以支持HTA从业者通过利益相关者在MD评估中的角色、价值观和贡献进行推理。该框架可转移到其他决策环境,并促进更加透明和包容的审议。
{"title":"Guiding stakeholder involvement in health technology assessment for medical devices: A novel approach for clarifying stakeholders’ roles and contributions","authors":"Liliana Freitas ,&nbsp;Mónica D. Oliveira ,&nbsp;Ana C.L. Vieira","doi":"10.1016/j.hlpt.2025.101075","DOIUrl":"10.1016/j.hlpt.2025.101075","url":null,"abstract":"<div><h3>Objectives</h3><div>Stakeholder involvement is recognized as essential in Health Technology Assessment (HTA), yet engagement remains insufficient, particularly in medical device (MD) evaluations. Literature on how to systematically identify and integrate stakeholders remains scarce. This study proposes a reflective framework to support HTA practitioners think about stakeholder inclusion and applies it to explore perspectives within the medical device context in Portugal.</div></div><div><h3>Methods</h3><div>We adapted Ulrich’s Critical Systems Heuristics (CSH) as a conceptual lens to structure reflection on stakeholder roles and contributions in MD HTA. The framework is organized around four sources of influence (motivation, control, knowledge, and legitimacy) and was operationalized through 26 semi-structured interviews with experts from Portugal’s HTA agency, hospitals, patient associations, and industry. Interview data were analysed using directed content analysis and the Framework Method, allowing to contrast current ('is') and ideal ('ought') views within each source of influence. The common themes were then used to construct interpretative narratives that captured rationales for stakeholder inclusion.</div></div><div><h3>Results</h3><div>The application of the framework revealed context-specific insights into stakeholder engagement in MD evaluation. Findings show stakeholder roles in MD evaluations extend beyond traditional classifications. For each CSH source of influence, rationales and conditions for stakeholder engagement were identified. Under motivation, stakeholders identified diverse purposes and measures of success, ranging from improved patient access to innovation to system-wide resource optimization. Under control, providers, purchasers, and payers were seen as central decision-makers, yet ideal processes included multidisciplinary governance and clearer procedural support. Under knowledge, multiple actors (including patients) were valued as contributors of contextual expertise, but gaps were highlighted in methodological tools. Under legitimacy, patients and the public were underrepresented and called for stronger mechanisms for direct involvement and broader societal alignment. Across all sources of influence, significant gaps were found between current practices and stakeholder expectations to highlight areas for development.</div></div><div><h3>Conclusions</h3><div>Rather than prescribing fixed engagement procedures, the proposed reflective framework offers a structured lens to support HTA practitioners in reasoning through stakeholder roles, values, and contributions in MD evaluations. The framework is transferable to other decision-making contexts and fosters more transparent and inclusive deliberation.</div></div>","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"14 6","pages":"Article 101075"},"PeriodicalIF":3.7,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144763983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An impact evaluation of the Scottish take-home naloxone programme 苏格兰纳洛酮带回家方案的影响评价
IF 3.7 3区 医学 Q1 HEALTH POLICY & SERVICES Pub Date : 2025-07-18 DOI: 10.1016/j.hlpt.2025.101072
Tobias Joseph Adams , Joseph Tay Wee Teck , Alexander Baldacchino , Patrice Forget

Objectives

To describe the change in opioid-related deaths (ORDs) recorded across Scotland since National ‘Take Home’ Naloxone Programme (NNP) implementation between baseline pre-implementation (2006 – 2010) and 10-year post implementation (2011 – 2020) periods. To describe and contextualise the change in ORDs within 4 weeks of prison release and hospital discharge across the same pre- and post-implementation periods and evaluate the reach of naloxone to people at risk of opioid overdose during this period.

Methods

Descriptive statistics as part of a pre-post secondary contribution analysis approach. The Better Evaluation Rainbow Framework for impact evaluation was utilised and data was obtained from official statistics and monitoring reports via Public Health Scotland.

Results

An increase in total ORDs nationwide was observed post-NNP implementation. In 2006–10, 9·8 % of ORDs (193 of 1970) were in people released from prison within 4 weeks of death, whereas only 4·4 % of ORDs (281 of 6439) in 2011–20 followed prison release, representing a 55 % reduction. A similar reduction in ORDs following hospital discharge was not observed. Cumulative reach of take-home naloxone to individuals at risk of opioid overdose across the post-implementation period was 58 %.

Conclusions

Implementation of the Scottish NNP has coincided with an increase in total ORDs nationwide, increased availability of take-home naloxone for management of opioid overdose and a reduction in the proportion of opioid-related fatalities among recently released prisoners. Unfortunately, the proportion ORDs after hospital discharge remain unchanged suggesting that this population may benefit from further research and additional distribution approaches.
目的描述自全国“带回家”纳洛酮计划(NNP)实施以来,在实施前基线(2006 - 2010)和实施后10年(2011 - 2020)期间,苏格兰各地记录的阿片类药物相关死亡(ORDs)的变化。描述和说明在同一实施前和实施后的4周内出狱和出院后口服药物摄入量的变化,并评估在此期间有阿片类药物过量风险的人获得纳洛酮的范围。方法描述性统计作为中学前后贡献分析方法的一部分。利用更好的评价彩虹框架进行影响评价,数据来自苏格兰公共卫生部的官方统计数据和监测报告。结果nnp实施后,全国ORDs总数有所增加。2006 - 2010年,9.8%的残疾人士(1970年有193人)是在死亡后4周内从监狱释放的,而2011 - 2020年只有4.4%的残疾人士(6439人中有281人)是在监狱释放后获得残疾人士的,减少了55%。出院后,没有观察到类似的ORDs减少。在实施后期间,有阿片类药物过量风险的个体累计获得纳洛酮的覆盖率为58%。苏格兰NNP的实施恰逢全国范围内ord总数的增加,用于管理阿片类药物过量的纳洛酮的可得性增加,以及最近释放的囚犯中阿片类药物相关死亡比例的减少。不幸的是,出院后发生ord的比例保持不变,这表明这一人群可能受益于进一步的研究和其他分布方法。
{"title":"An impact evaluation of the Scottish take-home naloxone programme","authors":"Tobias Joseph Adams ,&nbsp;Joseph Tay Wee Teck ,&nbsp;Alexander Baldacchino ,&nbsp;Patrice Forget","doi":"10.1016/j.hlpt.2025.101072","DOIUrl":"10.1016/j.hlpt.2025.101072","url":null,"abstract":"<div><h3>Objectives</h3><div>To describe the change in opioid-related deaths (ORDs) recorded across Scotland since National ‘Take Home’ Naloxone Programme (NNP) implementation between baseline pre-implementation (2006 – 2010) and 10-year post implementation (2011 – 2020) periods. To describe and contextualise the change in ORDs within 4 weeks of prison release and hospital discharge across the same pre- and post-implementation periods and evaluate the reach of naloxone to people at risk of opioid overdose during this period.</div></div><div><h3>Methods</h3><div>Descriptive statistics as part of a pre-post secondary contribution analysis approach. The Better Evaluation Rainbow Framework for impact evaluation was utilised and data was obtained from official statistics and monitoring reports via Public Health Scotland.</div></div><div><h3>Results</h3><div>An increase in total ORDs nationwide was observed post-NNP implementation. In 2006–10, 9·8 % of ORDs (193 of 1970) were in people released from prison within 4 weeks of death, whereas only 4·4 % of ORDs (281 of 6439) in 2011–20 followed prison release, representing a 55 % reduction. A similar reduction in ORDs following hospital discharge was not observed. Cumulative reach of take-home naloxone to individuals at risk of opioid overdose across the post-implementation period was 58 %.</div></div><div><h3>Conclusions</h3><div>Implementation of the Scottish NNP has coincided with an increase in total ORDs nationwide, increased availability of take-home naloxone for management of opioid overdose and a reduction in the proportion of opioid-related fatalities among recently released prisoners. Unfortunately, the proportion ORDs after hospital discharge remain unchanged suggesting that this population may benefit from further research and additional distribution approaches.</div></div>","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"14 6","pages":"Article 101072"},"PeriodicalIF":3.7,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144721585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Health Policy and Technology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1